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INTRODUCTION 
Analytical chemistry [1] is often described as the area of chemistry responsible for characterizing 
the composition of matter, both qualitatively (what is present) and quantitatively (how much is 
present).Analytical chemistry is not a separate branch of chemistry, but simply the application of 
chemical knowledge. 
Pharmaceutical Analysis [2] is the branch of chemistry involved in separating, identifying and 
determining the relative amounts of the components making up a sample of matter. It is mainly 
involved in the qualitative identification or detection of compounds and quantitative 
measurements of the substances present in bulk and pharmaceutical preparation. 
Quantitative analysis constitutes the largest part of analytical chemistry and is related to the 
various methods and instrumentation employed in determining the amounts or concentration of 
constituents in samples. It is also one of the basic criteria in the field of pharmacy where quality 
is to be critically maintained. Analytical chemistry may be defined as the “Science and art of 
determining the composition of materials in terms of the elements or compounds contained”. 
Analytical method is a specific application of a technique to solve an analytical problem [3]. 
Physico-chemical methods [4, 5] are used to study the physical phenomenon that occurs as a result 
of chemical reactions. Among the Physico-chemical methods, the most important are optical 
(Refractometry, Polarimetry, Emission, Fluorescence methods of analysis, Photometry including 
Photo-colorimetry and Spectrophotometry covering UV-Visible and IR regions and 
Nephelometry or Turbidimetry) and chromatographic (Column, Paper, TLC, GLC, HPLC) 
methods. Methods such as Nuclear Magnetic Resonance and Para Magnetic Resonance are 
becoming more and more popular. The combination of Mass Spectroscopy with Gas 
Dept. of Pharmaceutical Analysis                                                                                                      Introduction                             
 
KMCH college of pharmacy  Page 2    
Chromatography and Liquid Chromatography are the most powerful tools available. The 
chemical methods include the gravimetric and volumetric procedures which are based on 
complex formation; acid-base, precipitation and redox reactions. Titrations in non-aqueous 
media and complexometry have also been used in pharmaceutical analysis.  
The number of new drugs is constantly growing. This requires new methods for controlling their 
quality. Modern pharmaceutical analysis must need the following requirements. 
I. The analysis should take a minimal time. 
II. The accuracy of the analysis should meet the demands of Pharmacopoeia. 
III. The analysis should be economical. 
IV. The selected method should be precise and selective. 
These requirements are met by the Physico-chemical methods of analysis, a merit of which is 
their universal nature that can be employed for analyzing organic compounds with a diverse 
structure. Of them, Visible Spectrophotometry is generally preferred especially by small scale 
industries as the cost of the equipment is less and the maintenance problems are minimal. 
Pharmaceutical analysis techniques are applied mainly in two areas [6]: 
Traditionally, analytical chemistry has been split into two main types, Qualitative and 
Quantitative 
1. Qualitative: Qualitative analysis seeks to establish the presence of a given element or 
compound in a sample. 
2. Quantitative: Quantitative analysis seeks to establish the amount of a given element or 
compound in a sample. 
Dept. of Pharmaceutical Analysis                                                                                                      Introduction                             
 
KMCH college of pharmacy  Page 3    
Instrumental methods of Chemical analysis: 
Instrumental method is an exciting and fascinating part of chemical analysis that interacts with 
all areas of chemistry and with many other areas of pure and applied sciences. Analytical 
instrumentation plays an important role in the production and evaluation of new products and in 
the protection of consumers and environment. This instrumentation provides lower detection 
limits required to assure safe foods, drugs, water and air. Instrumental methods are widely used 
by analytical chemists to save time, to avoid chemical separation and to obtain increased 
accuracy. Different types of techniques are listed below: 
A) Spectrometric techniques: 
o Atomic Spectrometry (emission and absorption) 
o Electron Spin Resonance Spectroscopy 
o Fluorescence and Phosphorescence Spectrophotometry 
o Infrared Spectrophotometry 
o Nuclear Magnetic Resonance Spectroscopy 
o Radiochemical Techniques including activation analysis 
o Raman Spectroscopy 
o Ultraviolet and Visible Spectrophotometry 
o X-Ray Spectroscopy 
B) Chromatographic Techniques: 
o Gas Chromatography 
o High Performance Liquid Chromatography 
o Thin Layer Chromatography 
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C) Miscellaneous Techniques: 
o Kinetic Techniques 
o Mass Spectrometry 
o Thermal Analysis 
D) Hyphenated Techniques: 
o GC-MS (Gas Chromatography – Mass Spectrometry). 
o ICP-MS (Inductivity Coupled Plasma- Mass Spectrometry). 
o GC-IR (Gas Chromatography – Infrared Spectroscopy). 
o MS-MS (Mass Spectrometry – Mass Spectrometry). 
 
INTRODUCTION TO CHROMATOGRAPHY [7]: 
Chromatography, by classical definition, is a separation process where resolution is achieved by 
the distribution of the components of a mixture between two phases, a stationary phase and a 
mobile phase. Those components held preferentially in the stationary phase are retained longer in 
the system than those that are distributed in the mobile phase. As a consequence solutes are 
eluted from the system in the order of their increasing distribution coefficients with respect to the 
stationary phase. The mobile phase can be a gas or a liquid which gives rise to the two basic 
forms of Chromatography, namely, Gas Chromatography (GC) and Liquid Chromatography 
(LC). The stationary phase can also take two forms, solid and liquid, which provides two 
subgroups of GC and LC, namely; Gas-Solid Chromatography (GSC) and Gas-Liquid 
Chromatography (GLC), together with Liquid Solid Chromatography (LSC) and Liquid- Liquid 
Chromatography (LLC). 
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INTRODUCTION -HIGH PERFORMANCE LIQUID CHROMATOGRAPHY [8, 9]: 
In the modern pharmaceutical industry, HPLC is a major analytical tool applied at all stages of 
drug discovery, development and production. Fast and effective development of rugged 
analytical HPLC methods is more efficiently undertaken with a thorough understanding of HPLC 
principles, theory and instrumentation. 
Principle [10]:  
The principle of separation in normal phase mode and reverse phase mode is adsorption. When 
mixtures of components are introduced in to a HPLC column, they travel according to their 
relative affinities towards the stationary phase. The component which has more affinity towards 
the adsorbent travels slower. 
Types of HPLC [11]: 
There are many ways to classify Liquid Column Chromatography. If classification is based on 
the nature of the stationary phase and the separation process, 
Three modes can be specified: 
In Adsorption Chromatography: 
The stationary phase is an adsorbent (like silica gel or any other silica based packing) and the 
separation is based on repeated adsorption desorption steps. 
In Ion-Exchange Chromatography: 
1. The stationary bed has an ionically charged surface of opposite charge to the sample ions. 
2. This technique is used almost exclusively with ionic or ionizable samples. 
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3. The stronger the charge on the sample, the stronger it will be attracted to the ionic surface and 
thus, the longer it will take to elute. 
4. The mobile phase is an aqueous buffer, where both pH and ionic strength are used to control 
elution time. 
In Size Exclusion Chromatography: 
1. The column is filled with material having precisely controlled pore sizes, and the sample is 
simply screened or filtered according to its solvated molecular size. 
2. Larger molecules are rapidly washed through the column; smaller molecules penetrate inside 
the porous of the packing particles and elute later. 
3. Concerning the first type, two modes are defined depending on the relative polarity of the two 
phases: Normal and Reversed-Phase Chromatography. 
In Normal-Phase Chromatography: 
1. The stationary bed is strongly polar in nature (e.g., silica gel), and the mobile phase is non-
polar (such as n-hexane or tetrahydrofuran). 
2. Polar samples are thus retained on the polar surface of the column packing longer than less 
polar materials. 
In Reversed-Phase Chromatography: 
The stationary bed is non-polar in nature, while the mobile phase is a polar liquid, such as 
mixtures of Water and Methanol or Acetonitrile. Here the more non-polar the material is, the 
longer it will be retained. The component which has less affinity towards the stationary phase 
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travels faster. Since no two components have the same affinity towards the stationary phase, the 
components are separated. 
Liquid Chromatography (LC), which is one of the forms of Chromatography, is an 
analytical technique that is used to separate a mixture in solution into its individual components. 
The separation relies on the use of two different "phases" or "immiscible layers," one of which is 
held stationary while the other moves over it. Liquid Chromatography is the generic name used 
to describe any chromatographic procedure in which the mobile phase is a liquid. The separation 
occurs because, under an optimum set of conditions, each component in a mixture will interact 
with the two phases differently relative to the other components in the mixture. HPLC is the term 
used to describe Liquid Chromatography in which the liquid mobile phase is mechanically 
pumped through a column that contains the stationary phase.  
An HPLC instrument, therefore, consists of an injector, a pump, a column, and a detector given 
in the Fig: 1. 
Liquid Chromatography has come a long way with regard to the practical development of HPLC 
instrumentation and the theoretical understanding of different mechanisms involved in the 
analyte retention as well as the development of adsorbents with different geometries and surface 
chemistry.  
In HPLC, a liquid sample or a solid sample dissolved in a suitable solvent is carried through a 
Chromatographic column by a liquid mobile phase. Separation is determined by 
solute/stationary-phase interactions, including liquid–solid adsorption, liquid–liquid partitioning, 
ion exchange and size exclusion, and by solute/ mobile-phase interactions, which are listed in 
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Table: 1 with their applications. In each case, however, the basic instrumentations are essentially 
same. 
Table no: 1 Various Types of HPLC 
 
TYPE 
 
SAMPLE 
POLARITY 
MOLECU
LAR 
WEIGHTR
ANGE 
 
STATIONARY PHASE 
 
MOBILE 
PHASE 
Adsorption non-polar to 
somewhat 
polar 
100– 104 silica or alumina non-polar 
to polar 
Partition 
(reversed-
phase) 
non-polar to 
somewhat 
polar 
100– 104 non-polar liquid adsorbed 
or chemically bonded to 
the packing material 
relatively 
polar 
Partition 
(normal-
phase) 
somewhat 
polar to 
highly polar 
100– 104 highly polar liquid 
adsorbed or chemically 
bonded to the packing 
material 
relatively 
non-polar 
Ion 
Exchange 
highly polar 
to ionic 
100 – 104 ion-exchange resins made 
of insoluble, high-
molecular weight solids 
functionalized typically 
with sulfonic acid 
(cationic exchange) or 
amine (anionic exchange) 
groups 
aqueous 
buffers 
with 
added 
organic 
solvents to 
moderate 
solvent 
strength 
Size-
Exclusion 
non-polar to 
ionic 
103 – 106 small, porous, silica or 
polymeric particles 
polar to 
non-polar 
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Fig: 1 HPLC BASIC INSTRUMENT [12] 
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Various components involved in HPLC: 
1. Solvent delivery systems: 
The purpose of the pump, or solvent delivery system, is to ensure the delivery of a precise, 
reproducible, constant, and pulse-free flow of mobile phase.  
There are two classes of HPLC pumps: 
1. Constant pressure pumps  
2. Constant flow pumps 
The most common type of HPLC constant flow pump is the reciprocating piston pump, in which 
a piston is driven in and out of the solvent chamber by a gear. On the forward stroke, the inlet 
check valve closes, the outlet check valve opens, and the mobile phase is pumped to the column. 
On the return stroke, the check valves reverse and solvent is drawn into the chamber. In the 
single head reciprocating pump, 50 % of the time the mobile phase flows to the column and 50 
% of time the chamber is refilling. With the twin-head reciprocating pump the pump heads 
operate simultaneously but 1800 out of phase with each other. As a result mobile phase flows to 
the column 100 % of the time, providing an essentially pulse less flow.  
Most separations can be done using isocratic elution which is the use of a single-solvent system 
that does not change during the analysis. For more complex analysis gradient elution is required. 
Gradient elution can be generated in three ways. In all cases a computer controlled pumping 
system is required. In the first phase, controlled amounts of each eluent are metered into a 
mixing chamber before reaching the high-pressure pump which sends the mixture to the column. 
In second case the amount of each solvent is regulated by a proportionating valve which is 
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controlled by a microprocessor. The mixed solvent then enters the high pressure pump and flows 
to the column. In the third case the delivery of high delivery multiple pumps is controlled 
individually with a programming device and mixer is send to high-pressure mixing chamber 
2. Columns [13]: The heart of the system is the column. The choice of common packing material 
and mobile phases depend on the physical properties of the drug. The column selection flow 
chart can assist one in determining which columns to examine. Many different reverse phase 
columns will provide excellent specificity for any particular separation. It is therefore best to 
routinely attempt separations with a standard C-8 or C-18 column (e.g. Zorbax RX C-8) and 
determine if it provides good separations. If this column does not provide good separation or the 
mobile phase is unsatisfactory, alternate methods or columns should be explored. Reverse phase 
column differ by the carbon chain lengths, degree of end capping and percent carbon loading. 
Diol, Cyano and amino groups can be used for Reverse Phase Chromatography.The most 
commonly used columns for HPLC are constructed from stainless steel with internal diameters 
between 2.1 mm and 4.6 mm, and lengths ranging from approximately 30 mm to 300 mm. These 
columns are packed with 3–10 mm porous silica particles that may have an irregular or spherical 
shape. Typical column efficiencies are 40,000–60,000 theoretical plates/m. Micro columns use 
less solvent and, because the sample is diluted to a lesser extent, produce larger signals at the 
detector. These columns are made from fused silica capillaries with internal diameters of 44–200 
mm and lengths of up to several meters. Micro columns packed with 3–5 mm particles have been 
prepared with column efficiencies of up to 250,000 theoretical plates. Open tubular micro 
columns also have been developed, with internal diameters of1–50 mm and lengths of 
approximately 1 m. These columns, which contain no packing material, may be capable of 
obtaining column efficiencies of up to 1 million theoretical plates. The development of open 
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tubular columns, however, has been limited by the difficulty of preparing columns with internal 
diameters less than 10 mm. 
3. Stationary Phases [14]: 
In Liquid–Liquid Chromatography the stationary phase is a liquid film coated on a packing 
material consisting of 3–10 mm porous silica particles. The stationary phase may be partially 
soluble in the mobile phase, causing it to “bleed” from the column over time. To prevent this loss 
of stationary phase, it is covalently bound to the silica particles. Bonded stationary phases are 
attached by reacting the silica particles with an organochlorosilane of the general form Si 
(CH3)2RCl, where R is an alkyl or substituted alkyl group. To prevent unwanted interactions 
between the solutes and any unreacted –SiOH groups, the silica frequently is “capped” by 
reacting it with Si (CH3)3Cl; such columns are designated as end-capped. The properties of a 
stationary phase are determined by the nature of theorganosilane’s alkyl group. If R is a polar 
functional group, then the stationary phase will be polar. Since the stationary phase is polar, the 
mobile phase is a non-polar or moderately polar solvent. The combination of a polar stationary 
phase and a non-polar mobile phase is called normal phase Chromatography. 
In reverse phase Chromatography, which is the more commonly encountered form of HPLC, the 
stationary phase is non-polar and the mobile phase is polar. The most common non-polar 
stationary phases use an organochlorosilane for which the R group is an n-octyl (C8) or n-
octyldecyl (C18) hydrocarbon chain. Most reverse phase separations are carried out using a 
buffered aqueous solution as a polar mobile phase.  
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4. Mobile Phases (15) 
The elution order of solutes in HPLC is governed by polarity. In a normal-phase separation the 
least polar solute spends proportionally less time in the polar stationary phase and is the first 
solute to elute from the column.  
The mobile phases used in normal-phase chromatography are based on non-polar hydrocarbons, 
such as hexane, heptane, or octane, to which is added a small amount of a more polar solvent, 
such as 2-propanol. Solvent selectivity is controlled by the nature of the added solvent. Additives 
with large dipole moments, such as methylene chloride and 1, 2-dichloroethane, interact 
preferentially with solutes that have large dipole moments, such as nitro-compounds, nitriles, 
amines, and sulfoxides. Good proton donors such as Chloroform, m-Cresol, and Water interact 
preferentially with basic solutes such as amines and Sulfoxides, whereas good proton acceptors 
such as alcohols, ethers, and amines tend to interact best with hydroxylated molecules such as 
acids and phenols. A variety of solvents used as mobile phases in normal-phase Chromatography 
are listed in Table: 1.2, some of which may need to be stabilized by addition of an antioxidant, 
such as 3-5 % Ethanol, because of the propensity for peroxide formation. 
In a reverse-phase separation the order of elution is reversed, with the most polar solute being the 
first to elute. The mobile phases used in reversed-phase Chromatography are based on a polar 
solvent, typically water, to which a less polar solvent such as Acetonitrile or Methanol is added. 
Solvents with large dipole moments, such as methylene chloride and 1,2-dichloroethane, interact 
preferentially with solutes that have large dipole moments, such as nitro- compounds, nitriles, 
amines, and sulfoxides. Solvents that are good proton donors, such as Chloroform, m-Cresol, and 
Water, interact preferentially with basic solutes such as amines and Sulfoxides, and solvents that 
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are good proton acceptors, such as alcohols, ethers, and amines tend to interact best with 
hydroxylated molecules such as acids and phenols.    
Table: 2 List of solvents used in HPLC 
Solvent          Adsorption energy(e0)  
                                    on Al2O3 
Solvent               Adsorption energy(e0)   
                                               on Al2O3 
n-Pentane                              0.00 
Isooctane                               0.01 
Cyclohexane                         0.04 
Carbon Tetrachloride         0.18 
Toluene                                 0.29 
Benzene                                 0.32 
Chloroform                           0.40 
Methyl Ethyl Ketone             0.51 
Acetone                                      0.56 
Ethyl Acetate                             0.58 
Dimethylamine                          0.63 
Acetonitrile                                0.65 
Ethanol                                       0.88 
Methanol                                    0.95 
Acetic Acid                              Large 
Water                                     Very large 
 
5. Detectors [16] 
The detection of UV light absorbance offers both convenience and sensitivity for molecules. 
When a chromophore, the wavelength of detection for a drug should be based on its UV 
spectrum in the mobile phase and not in pure solvents, the most selective wavelength for 
detecting a drug is frequently the longest wavelength maximum to avoid interference from 
solvents, buffers and excipients. Other method of detection can be useful are required in some 
instances. 
• Solute specific detectors (UV, Visible, Fluorescence, Electrochemical, IR, Radioactivity). 
• Bulk property detectors (Refractive index, Viscometric, Conductivity). 
• Desolvation detectors (Flame ionization etc.). 
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• LC-MS detectors. 
•  Reaction detectors. 
SYSTEM SUITABILITY PARAMETERS [17] 
System suitability tests are an integral part of Gas and Liquid Chromatography.  They are used to 
verify that the resolution and reproducibility of the Chromatographic system are adequate for the 
analysis to be done. These tests are based on the concept that the equipment, electronics, 
analytical operations and samples to be analyzed constitute an integral system that can be 
evaluated as such. 
There are numerous guidelines which detail the expected limits for typical Chromatographic 
methods. In the current FDA guideline on “Validation of Chromatographic methods” the 
following acceptance limits are proposed as initial criteria. 
1. Capacity factor (k'): 
k' = (t R- t0) / t 0 
The capacity factor is a measure of the degree of retention of an analyte relative to an unretained 
peak. 
Where, tR- retention time for the sample peak. 
t0- retention time for the unretained peak. 
The peak should be well-resolved from other peaks and the void volume. Generally the value of 
k' is > 2. 
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2. Backpressure: 
The pressure required to pump the mobile phase through the column. It is related to mobile phase 
viscosity (η), flow rate (F), column length (L), and diameter (dc), and particle size (dp) by the 
following equation: 
                                            ΔP α FLη / dp2 dc2  
3. Resolution (Rs): 
Ability of a column to separate chromatographic peaks, Resolution can be improved by 
increasing column length, decreasing particle size, increasing temperature, changing the eluent or 
stationary phase. It can also be expressed in terms of the separation of the apex of two peaks 
divided by the tangential width average of the peaks. 
Rs = ΔtR / 0.5 (W1 + W2); 
Where, ΔtR = t2 – t1.  
For reliable quantization, well-separated peaks are essential for quantitation. Rs of > 2 between 
the peak of interest and the closest potential interfering peak (impurity, excipients, degradation 
product, internal standard, etc.) are desirable. 
4. Theoretical plate number / Efficiency (N): 
A measure of peak band spreading determined by various methods, some of which are sensitive 
to peak asymmetry. The most common are shown here, with the ones most sensitive to peak 
shape shown first. 
4-sigma / tangential 
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N = 16 (tR / W) 2 = L / H 
Half height 
N = 5.54(tR/ W) 2 = L / H 
Theoretical plate number is a measure of column efficiency, that is, how many peaks can be 
located per unit run-time of the chromatogram. 
Where,    tR - Retention time for the sample peak. 
               W - Peak width. 
               N is fairly constant for each peak on a chromatogram with a fixed set of operating 
conditions. H (height), or HETP (height equivalent of a theoretical plate), measures the column 
efficiency per unit length (L) of the column. Parameters which can affect N or H include. 
Peak position, particle size in column, flow-rate of mobile phase, column temperature, viscosity 
of mobile phase, and molecular weight of the analyte. 
The theoretical plate number depends on elution time but in general should be > 2000. 
5. Tailing factor (T): 
It is the measure of the symmetry of a peak. 
T = W0.05 / 2f 
Where,      W0.05 - Peak width at 5% height  
                  F - Distance from peak front to apex point at 5% height. 
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The accuracy of quantitation decreases with increase in peak tailing because of the difficulties 
encountered by the integrator in determining where/when the peak ends and hence the 
calculation of the area under the peak.  
Limits -T</= 2. 
Advantages of HPLC [18]: 
The HPLC is the method of choice in the field of analytical chemistry, since this method is 
Specific, Robust, Linear, Precise and Accurate and the Limit of detection is low and also it offers 
the following advantages. 
1. Speed (many analysis can be accomplished in 20 min or less). 
2. Greater sensitivity (various detectors can be employed). 
3. Improved resolution (wide variety of stationary phases). 
4. Reusable columns (expensive columns but can be used for many analysis). 
5. Easy sample recovery, handling and maintenance. 
6. Instrumentation leads itself to automation and quantification (less time & less labour). 
7. Precise and reproducible and integrator itself does calculations. 
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Establishing documentation evidence, which provides a high degree of assurance that a specific 
process, will consistently produce a product meeting its predetermined specifications and quality 
attributes. 
2. World Health Organization (WHO): 
Action of providing that, any procedure, process, equipment, material, activity, or system 
actually leads to the expected results. 
3. European Committee (EC): 
Action of providing in accordance with the principles of good manufacturing practice that any 
procedure, process, equipment, material, activity or system actually leads to the expected results. 
In brief validation is a key process for effective Quality Assurance. 
Analytical method validation: 
Method validation is the process to confirm that the analytical procedure employed for a specific 
test is suitable for its intended use. Methods need to be validated or revalidated. 
Before their introduction into routine use 
• Whenever the conditions change for which the method has been validated, e.g., instruments 
with different characteristics.  
• Whenever the method is changed, and the change is outside the original scope of the method. 
The International Conference on Harmonization (ICH) of Technical Requirements for the 
Registration of Pharmaceutical for human use has developed a consensus text on the 
validation of analytical procedures. The document includes definitions for validation 
characteristics.  
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The parameters are: 
i. Precision 
ii. Specificity 
iii. Accuracy 
iv. Linearity 
v. Range 
vi. Limit of Detection 
vii. Limit of Quantitation 
viii. Robustness 
ix. Ruggedness 
The parameters as defined by the ICH and by other organizations are; 
Precision: 
“The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. Precision may be considered at three 
levels; repeatability, intermediate precision and reproducibility.” 
Precision should be obtained preferably using authentic samples. As parameters, the standard 
deviation (SD), the relative standard deviation (coefficient of variation) and the confidence 
interval should be calculated for each level of precision. 
Repeatability expresses the analytical variability under the same operating conditions over a 
short interval of time (within-assay, intra-assay). At least nine determinations covering the 
specified range or six determinations at 100% test concentration should be performed. 
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Intermediate precision includes the influence of additional random effects within laboratories, 
according to the intended use of the procedure, for example, different days, analysts or 
equipment, etc. 
Reproducibility, i.e., the precision between laboratories (collaborative or inter-laboratory 
Studies), is not required for submission, but can be taken into account for standardization of 
analytical procedures. 
Specificity: 
“Specificity is the ability to assess unequivocally the analyte in the presence of components 
which may be expected to be present. Typically these might include impurities, degradants, 
matrix, etc. Lack of specificity of an individual procedure may be compensated by other 
supporting analytical procedure(s)”. 
With respect to identification, discrimination between closely related compounds likely to be 
present should be demonstrated by positive and negative samples. In the case of chromatographic 
assay and impurity tests, available impurities/degradants can be spiked at appropriate levels to 
the corresponding matrix or else degraded samples can be used. For assay, it can be 
demonstrated that the result is unaffected by the spiked material. Impurities should be separated 
individually and/or from other matrix components. Specificity can also be demonstrated by 
verification of the result with an independent. In the case of chromatographic separation, 
resolution factors should be obtained for critical separation. Tests for peak homogeneity, for 
example, diode array detection (DAD) or mass spectrometry (MS) are recommended. 
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Accuracy: 
“The accuracy of an analytical procedure expresses the closeness of agreement between the 
value which is accepted either as a conventional true value or an accepted reference value and 
the value found”.  
Accuracy can be demonstrated by the following approaches: 
• Inferred from precision, linearity and specificity 
• Comparison of the results with those of a well characterized, independent procedure 
• Application to a reference material (for drug substance) 
• Recovery of drug substance spiked to placebo or drug product (for drug product).  
• Recovery of the impurity spiked to drug substance or drug product (for impurities). 
For the quantitative approaches, at least nine determinations across the specified range should be 
obtained, for example, three replicates at three concentration levels each. The percentage 
recovery or the difference between the mean and the accepted true value together with the 
confidence intervals are recommended. 
It is important to use the same quantitation method (calibration model) in the accuracy studies as 
used in the control test procedure. Sometimes in the literature, the data from linearity studies are 
simply used to calculate the content of spiked samples. However, the validation linearity study is 
usually not identical to the calibration applied in routine analysis. Again, validation has to 
demonstrate the suitability of the routine analytical procedure. Deviations from the theoretical 
recovery values, while performing a calibration with a drug substance alone, may indicate 
interferences between the analyte and placebo components, incomplete extraction, etc. In such a 
case, the calibration should be done with a synthetic mixture of placebo and drug substance 
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standard. Such interferences will also be detected by comparing the linearity’s of diluted drug 
substance and of spiked placebo, but the evaluation is more complex. In contrast, recovery 
studies usually concentrate directly on the working range and are simpler (but not always easy) 
to evaluate. 
Linearity: 
“The linearity of an analytical procedure is its ability (within a given range) to obtain test results 
which are directly proportional to the concentration (amount) of analyte in the sample”.  
It may be demonstrated directly on the analyte, or on spiked samples using at least five 
concentrations over the whole working range. Besides a visual evaluation of the analyte signal as 
a function of the concentration, appropriate statistical calculations are recommended, such as a 
linear regression. The parameters slope and intercept, residual sum of squares and the coefficient 
of correlation should reported. A graphical presentation of the data and the residuals is 
recommended. 
Range: 
“The range of an analytical procedure is the interval between the upper and lower concentration 
(amounts) of analyte in the sample (including these concentrations) for which it has been 
demonstrated that the analytical procedure has a suitable level of precision, accuracy and 
linearity.” 
 
 
Dept. of Pharmaceutical Analysis                                                                                                      Introduction                             
 
KMCH college of pharmacy  Page 25    
Limit of detection (LOD): 
“The detection limit of an individual analytical procedure is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. The quantitation 
limit of an individual analytical procedure is the lowest concentration of analyte in a sample 
which can be quantitatively determined with suitable precision and accuracy.”  
Various approaches can be applied: 
Visual definition 
        Calculation from the signal-to-noise ratio (LOD and LOQ correspond to 3 or2 and 10 
times the noise level, respectively) 
        Calculation from the standard deviation of the blank  
        Calculation from the calibration line at low concentrations 
LOD; LOQ ¼ F_SDb (2.6-1) 
F: factor of 3.3 and 10 for LOD and LOQ, respectively 
SD: standard deviation of the blank, standard deviation of the ordinate intercept, or residual 
standard deviation of the linear regression 
b: slope of the regression line 
The estimated limits should be verified by analyzing a suitable number of samples containing the 
analyte at the corresponding concentrations. The LOD or LOQ and the procedure used for 
determination, as well as relevant chromatograms, should be reported. 
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Limit of Quantitation (LOQ): 
The quantitation limit is the lowest level of analyte that can be accurately and precisely 
measured. This limit is required only for impurity methods and is determined by reducing the 
analyte concentration until a level is reached where the precision of the method is unacceptable. 
If not determined experimentally, the quantitation limit is often calculated as the analyte 
concentration that gives S/N = 10. An example of quantitation limit criteria is that the limit will 
be defined as the lowest concentration level for which an RSD 20% is obtained when an intra-
assay precision study is performed. 
Robustness: 
According to ICH Q2A [1a] “the robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small, but deliberate variations in method parameters and 
provides an indication of its reliability during normal usage”. 
Furthermore, it is stated in ICH Q2B [1b], “The evaluation of robustness should be considered 
during the development phase and depends on the type of procedure understudy. It should show 
the reliability of an analysis with respect to deliberate variations in method parameters. If 
measurements are susceptible to variations in analytical conditions, the analytical conditions 
should be suitably controlled or a precautionary statement should be included in the procedure. 
One consequence of the evaluation of robustness should be that a series of system suitability 
parameters (e.g., resolution test) is established to ensure that the validity of the analytical 
procedure is maintained whenever used”. 
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Ruggedness: 
“The ruggedness of an analytical method is the degree of reproducibility of test results obtained 
by the analysis of the same samples under a variety of conditions, such as different laboratories, 
different analysts, different instruments, different days, etc. Ruggedness is normally expressed as 
the lack of influence on test results of operational and environmental variables of the analytical 
method. Ruggedness is a measure of reproducibility of test results under the variation in 
conditions normally expected from laboratory to laboratory and from analyst to analyst”. The 
degree of reproducibility is then evaluated by comparison of the results obtained under varied 
conditions with those under standard conditions. 
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Table no: 3 Method Validation Requirements 
 
Method Validation Requirements 
 
 
Acceptance Criteria 
Precision 
• Assay repeatability                                  
• Intermediate precision (Ruggedness)    
 
 
≤ 1% RSD 
≤ 2% RSD 
Accuracy 
• Mean recovery per concentration          
 
 
100.0% ± 2.0% 
Limit of detection 
• Signal to-to-noise ratio                            
 
 
≥ 3:1 
Limit of quantification   
• Signal to-to-noise ratio                            
 
 
≥ 10:1 
Linearity/Range 
• Correlation coefficient                            
• y-Intercept                                               
• Visual                                                        
 
 
>0.99 
± 10% 
Linear 
Robustness 
• System suitability met                             
• Solution stability                                     
 
 
Yes 
± 2% change from time zero 
Specificity 
• Resolution from main peak                    
 
 
>2 min. (retention time) 
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LITERATURE REVIEW 
JIN Yi et al(2011) [26] developed a sensitive and rapid LC-MS/MS method to determine 
the concentration of tapentadol in rat plasma. Methods After the extraction from plasma by 
protein precipitation, analytes and internal standards were separated by a Diamonsil C18 column. 
Methanol-5 mmol·L-1 ammonium acetate-acetic acid (V׷V׷V=58׷42׷0.5) were used as the mobile 
phase. The multiple reactions monitoring (MRM) was used for quantitative determination in 
positive mode. The transitions were m/z: 222.2→107.1 for tapentadol ([M+H]+) , m/z: 
307.1→220.1 for fluconazol (IS, [M+H]+).  Results No significant interferences for the detection 
of tapentadol and fluconazol from endogenous substances in plasma were observed in the present 
study. The calibration curve was linear over the range of 2.0-200 μg·L-1 for tapentadol. The 
accuracy was in the range of 96.2%-97.5% and the inter-day and intra-day precision was less 
than 15%. Conclusions The LC-MS/MS method is simple, rapid and sensitive enough for the 
pharmacokinetic study of Tapentadol in rats 
 Thomas M. Tzschentke et al[27]   (_)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-
methyl-propyl)-phenol hydrochloride (Tapentadol HCl) is a novel _-opioid receptor (MOR) 
agonist (Ki _ 0.1 _M; relative efficacy compared with morphine 88% in a [35S]guanosine 5_-3-
O-(thio)triphosphate binding assay) and NE reuptake inhibitor (Ki _ 0.5 _M for synaptosomal 
reuptake inhibition). In vivo intracerebral microdialysis showed that tapentadol, in contrast to 
morphine, produces large increases in extracellular levels of NE (_450% at 10 mg/kg i.p.). 
Tapentadol exhibited analgesic effects in a wide range of animal models of acute and chronic 
pain [hot plate, tail-flick, writhing, Randall-Selitto, mustard oil colitis, chronic  constriction 
injury (CCI), and spinal nerve ligation (SNL)], with ED50 values ranging from 8.2 to 13 mg/kg 
after i.p. administration in rats. Despite a 50-fold lower binding affinity to MOR, the analgesic 
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potency of tapentadol was only two to three times lower than that of morphine, suggesting that 
the dual mode of action of tapentadol may result in an opiate-sparing effect. A role of NE in the 
analgesic efficacy of tapentadol was directly demonstrated in the SNL model, where the 
analgesic effect of tapentadol was strongly reduced by theα2-adrenoceptor antagonist yohimbine 
but only moderately attenuated by the MOR antagonist naloxone, whereas the opposite was seen 
for morphine. Tolerance development to the analgesic effect of tapentadol in the CCI model was 
twice as slow as that of morphine. It is suggested that the broad analgesic profile of tapentadol 
and its relative resistance to tolerance development may be due to a dual mode of action 
consisting of both MOR activation and NE reuptake inhibition. 
Rolf terlinden et al [28] proposed Tapentadol is a novel, centrally acting oral analgesic 
with a dual mode of action that has demonstrated efficacy in preclinical and clinical models of 
pain relief. The present study investigated and characterized the absorption, metabolism, and 
excretion of tapentadol in humans. Four healthy male subjects received a single 100-mg oral 
dose of 3-[14C]-labeled tapentadol HCl for evaluation of the pharmacokinetics of the drug and 
the excretion balance of radiocarbon. The concentration-time profiles of radiocarbon in whole 
blood and serum and radiocarbon excretion in the urine and feces, and the expired C02 were 
determined. The serum pharmacokinetics and excretion kinetics of tapentadol and its conjugates 
were assessed, as was its tolerability. Absorption was rapid (with a mean maximum serum 
concentration [Cmax], 2.45 μg-eq/m]; a time to Cmax, 1.25–1.5 h), and the drug was present 
primarily in the form of conjugated metabolites (conjugated: unconjugated metabolites = 24׷1). 
Excretion of radiocarbon was rapid and complete (>95% within 24 h; 99.9% within 5 days) and 
almost exclusively renal (99%׷69% conjugates; 27% other metabolites; 3% in unchanged form). 
No severe adverse events or clinically relevant changes in vital signs, laboratory measurements, 
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electrocardiogram recording, or physical examination findings were reported. In our study group, 
it was found that a single oral dose of tapentadol was rapidly absorbed, then excreted into the 
urine, primarily in the form of conjugated metabolites, and was well tolerated. 
Thomas M Tzschentke et al(2009) [29] stated that Tapentadol exerts its analgesic effects 
through micro opioid receptor agonism and nor-adrenaline reuptake inhibition in the central 
nervous system. Preclinical studies demonstrated that tapentadol is effective in a broad range of 
pain models, including nociceptive, inflammatory, visceral, mono- and polyneuropathic models. 
Moreover, clinical studies showed that tapentadol effectively relieves moderate to severe pain in 
various pain care settings. In addition, it was reported to be associated with significantly fewer 
treatment discontinuations due to a significantly lower incidence of gastrointestinal-related 
adverse events compared with equivalent doses of oxycodone. The combination of these reduced 
treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe 
nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing 
patient compliance with their treatment regimen. 
Xu Steven Xu  et al(2010) [30] Background Tapentadol is a new, centrally active 
analgesic agent with two modes of action - μ opioid receptor agonism and nor-epinephrine 
reuptake inhibition - and the immediate-release (IR) formulation is approved in the US for the 
relief of moderate to severe acute pain. The aims of this analysis were to develop a population 
pharmacokinetic model to facilitate the understanding of the pharmacokinetics of tapentadol IR 
in healthy subjects and patients following single and multiple dosing, and to identify covariates 
that might explain variability in exposure following oral administration. 
Methods: The analysis included pooled data from 11385 serum pharmacokinetic samples from 
1827 healthy subjects and patients with moderate to severe pain. Population pharmacokinetic 
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modeling was conducted using nonlinear mixed-effects modeling (NONMEM®) software to 
estimate population pharmacokinetic parameters and the influence of the subject's demographic 
characteristics, clinical laboratory chemistry values and disease status on these parameters. 
Simulations were performed to assess the clinical relevance of the covariate effects on tapentadol 
exposure. 
Results:  A two-compartment model with zero-order release followed by first-order absorption 
and first-order elimination best described the pharmacokinetics of tapentadol IR following oral 
administration. The inter-individual variability (coefficient of variation) in apparent oral 
clearance (CL/F) and the apparent central volume of distribution after oral administration were 
30% and 29%, respectively. An additive error model was used to describe the residual variability 
in the log-transformed data, and the standard deviation values were 0.308 and 0.314 for 
intensively and sparsely sampled data, respectively. Covariate analysis showed that sex, age, 
bodyweight, race, body fat, hepatic function (using total bilirubin and total protein as surrogate 
markers), health status and creatinine clearance were statistically significant factors influencing 
the pharmacokinetics of tapentadol. Total bilirubin was a particularly important factor that 
influenced CL/F, which decreased by more than 60% in subjects with total bilirubin greater than 
50μmol/L. 
Conclusions:  The population pharmacokinetic model for tapentadol IR identified the 
relationship between pharmacokinetic parameters and a wide range of covariates. The 
simulations of tapentadol exposure with identified, statistically significant covariates 
demonstrated that only hepatic function (as characterized by total bilirubin and total protein) may 
be considered a clinically relevant factor that warrants dose adjustment. None of the other 
covariates are of clinical relevance, nor do they necessitate dose adjustment.  
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Cooper et al [31] developed a sensitive LC-MS/MS method for the quantification of 
oxycodone, oxymorphone and noroxycodone which has been used to analyze clinical samples. 
The analytes are well separated on a typical C18, 5 micron HPLC column, but the cycle time of 9 
minutes is a hindrance to maximizing throughput. BASi has sought to improve cycle time while 
also improving resolution by converting the method to utilize an ultra small particle size C18 
column with a conventional HPLC. 
Methods: The range of the validated assay is 0.1-100 ng for oxycodone and oxymorphone, and 
0.5-100 ng/ml for noroxycodone. Detection is by positive Turbo Ion spray on a Sciex API-4000. 
The HPLC column is a 2.1 X 50 mm, 5 micron, Waters XBridge C18. Typical retention times of 
the analytes are oxycodone 5.2 minutes, oxymorphone 3.5 minutes, and noroxycodone 2.4 
minutes. The cycle time is approximately 9 minutes. For the new, faster method, the 
chromatography has been altered to accommodate the small particle column [2 x 30 mm, 1.5 
micron, Grace Vison HT C18] but the extraction and mass spectrometer conditions remain the 
same. The analytes are eluted on a steep gradient from 10 to 100% organic with a 1 minute hold 
at 5 minutes and a flow rate of 0.2 mL/min. 
             Arunadevi S. Birajdar(2009) [32] developed a high-performance liquid 
chromatographic method has been developed for the simultaneous analysis of paracetamol and 
tramadol in combined solid dosage form. The mobile phase consisting of Acetonitrile- 0.26 % 
Triethylamine buffer (pH 7.3) in ratio of (45:55 % v/v) was delivered at the flow rate of 1.0 
mL/min and UV detection was carried out at 264 nm. The separation was achieved using C18 
reverse-phase column (250 X 4.6 mm I.D., particle size 5µm). The method was linear over the 
concentration range of 1.0-12.0 µg/mL for Paracetmol and 0.1-1.2 µg/mL for tramadol. 
Domperidone was used as an internal standard (IS). The analytical recovery obtained was 
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99.88%.  The validation of method carried out as per ICH guidelines. The described HPLC 
method was successfully employed for the analysis of pharmaceutical formulations containing 
combined dosage form and can be employed for bioequivalence study in future for the same 
formulations. 
 
Markus G Gebauer et al(2001) [33] An HPLC method for the quantification of 
oxycodone and lidocaine in a gel matrix is described. The mobile phase consisted of methanol–
water–acetic acid (35:15:1 v/v/v) and was delivered at 1.5 ml/min through a 4.6×250 mm 
Zorbax® SB-C8 column. Oxycodone was detected at 285 nm and lidocaine at 264 nm. Linear 
calibration curves were obtained for oxycodone in the range of 0.05–1.5% (w/w) and for 
lidocaine in the range of 0.1–5.0% (w/w). Oxycodone and lidocaine were treated with hydrogen 
peroxide and the oxidation products were readily separated on the column. The method was 
applied to assess the stability of a gel containing oxycodone hydrochloride (0.3% w/w) and 
lidocaine (1.5% w/w). The gel was stored under refrigeration in ready-to-use syringes and under 
these conditions oxycodone and lidocaine were stable for at least 1 year. The gel is useful in the 
management of tenesmus in rectal cancer. 
Lambropoulos J et al(1999) [34]The stability indicating properties of the USP method for 
the assay of fentanyl in fentanyl citrate injection were evaluated [1] by analyzing fentanyl drug 
substance and product after acid, hydrogen peroxide, heat, and light treatment. N-phenyl-N-(4-
piperidinyl) propionamide (PPA), which is a known degradation product/process impurity of 
fentanyl, was not adequately resolved from the fentanyl peak, and mobile phase adjustments did 
not improve the resolution (Fig. 1). Therefore, the USP method did not meet the requirements for 
a stability-indicating assay. In addition, the wavelength in the USP method was too high (230 
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nm) to provide adequate levels for the quantitation of the related substances of fentanyl and, in 
addition, the acetate ions in the mobile phase could interfere with a lower wavelength detection. 
An isocratic, reversed phase, stability indicating, high performance liquid chromatographic 
(HPLC) method for the assay of fentanyl and related substances in fentanyl citrate injection, USP 
has been developed and validated. The chromatographic conditions employed an Inertsil C8, 5 
column (25 cm x 4.6 mm), a mobile phase of aqueous perchloric acid [0.23%, w/v]-Acetonitrile 
[65:35, v/v], and ultraviolet (UV) detection at 206 nm. Under the chromatographic conditions of 
the method, PPA and seven other known process impurities were separated from the active. 
Degradation studies showed that the active eluted as a spectrally pure peak resolved from its 
degradation products. 
John Lambropoulos et al(2000) [35] A high performance liquid chromatography (HPLC) 
method for the assay of fentanyl citrate, alfentanil hydrochloride, and sufentanil citrate swab 
samples was developed and validated in order to control a cleaning procedure. The swabbing 
procedure involved Super POLX 1200 wipers moistened with water. The assay employed 
extraction of swabs with water and analysis by isocratic, reversed-phase, HPLC with varying 
ultraviolet (UV) detection for desired sensitivity, depending on the analyte. The method was 
shown to be selective and linear from the limits of quantitation (0. 10, 0. 20, and 0.15 μg/swab 
for fentanyl citrate, alfentanil, and sufentanil, respectively) to over three times these 
concentrations. The assay limits (detection levels) per swab area were set at least at 0.2% of the 
concentrations of the actives in the drug products (0.02, 0. 10, and 0. 10 μg/swab or 
approximately 0.03, 0.02, and 0.2% for fentanyl citrate, alfentanil, and sufentanil, respectively). 
It should be noted that all active concentrations listed in this work were calculated based on the 
salt form concentration for fentanyl (citrate salt) and the free base forms for alfentanil and 
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sufentanil. No reference standard was available for alfentanil hydrochloride and sufentanil 
citrate. Drug product was used instead throughout this study. 
J Lambropoulos et al(1999)[36] proposed the stability indicating properties of the USP 
method for the assay of fentanyl in fentanyl citrate injection were evaluated [1] by analyzing 
fentanyl drug substance and product after acid, hydrogen peroxide, heat, and light treatment. N-
phenyl-N-(4-piperidinyl) propionamide (PPA), which is a known degradation product/process 
impurity of fentanyl, was not adequately resolved from the fentanyl peak, and mobile phase 
adjustments did not improve the resolution (Fig. 1). Therefore, the USP method did not meet the 
requirements for a stability-indicating assay. In addition, the wavelength in the USP method was 
too high (230 nm) to provide adequate levels for the quantitation of the related substances of 
fentanyl and, in addition, the acetate ions in the mobile phase could interfere with a lower 
wavelength detection. An isocratic, reversed phase, stability indicating, high performance liquid 
chromatographic (HPLC) method for the assay of fentanyl and related substances in fentanyl 
citrate injection, USP has been developed and validated. The chromatographic conditions 
employed an Inertsil C8, 5 column (25 cm x 4.6 mm), a mobile phase of aqueous perchloric acid 
[0.23%, w/v]-Acetonitrile [65:35, v/v], and ultraviolet (UV) detection at 206 nm. Under the 
chromatographic conditions of the method, PPA and seven other known process impurities were 
separated from the active. Degradation studies showed that the active eluted as a spectrally pure 
peak resolved from its degradation products.  
Amir mehdizadeh et al(2005) [37] developed a simple, sensitive and specific HPLC 
method and also a simple and fast extraction procedure were developed for quantitative analysis 
of fentanyl transdermal patches. Chloroform, methanol and ethanol were used as extracting 
solvents with recovery percent of 92.1, 94.3 and 99.4% respectively. Fentanyl was extracted with 
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ethanol and the eluted fentanyl through the C18 column was monitored by UV detection at 230 
nm. The linearity was at the range of 0.5-10 μg/mL with correlation coefficient (r2) of 0.9992. 
Both intra and inter-day accuracy and precision were within acceptable limits. The detection 
limit (DL) and quantitation limit (QL) were 0.15 and 0.5 μg/mL, respectively. Other validation 
characteristics such as selectivity, robustness and ruggedness were evaluated. Following method 
validation, a system suitability test (SST) including capacity factor (k´), plate number (N), tailing 
factor (T), and RSD was defined for routine test. 
 
 
Finally after searching of the all literature no method was developed for estimation of 
Tapentadol Hydrochloride by RP-HPLC. So by this, I have decided to do method 
development on this drug by RP-HPLC. 
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       Metabolism : Hepatic glucuronidation and sulfate conjugation  
       Half-life  : 4 hrs 
       Excretion  : Renal (>95%) and feca 
       Routes       : Oral, Oral, Other ROA Unknown 
Description: 
    White or off white powder 
Category [40]: 
    Centrally acting analgesic, agonist at the m-opioid receptor, 
Dose [41]: 
Immediate release:  
50 mg, 75 mg, or 100 mg orally every 4 to 6  
Extended release:  
Opioid naive: Initial: 50 mg twice daily (recommended interval: 12 hours); titrate in increments 
of 50 mg no more frequently than twice daily every 3 days to effective dose (therapeutic range: 
100 to 250 mg twice daily) (maximum dose: 500 mg/day) 
5.2 Pharmacological profile [42] 
      Mechanism of action: 
            Tapentadol is a centrally-acting synthetic analgesic. Although its exact mechanism is 
unknown, analgesic efficacy is thought to be due to mu-opioid agonist activity and the inhibition 
of nor-epinephrine reuptake. 
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controlled crossover study, healthy subjects were administered five consecutive doses of 
Nucynta® 100 mg every 6 hours, Nucynta® 150 mg every 6 hours, placebo and a single oral 
dose of moxifloxacin. Similarly, Nucynta® had no relevant effect on other ECG parameters 
(heart rate, PR interval, QRS duration, and T-wave or U-wave morphology). 
Pharmacokinetics 
Absorption 
Mean absolute bioavailability after single-dose administration (fasting) is approximately 32% 
due to extensive first-pass metabolism. Maximum serum concentrations of tapentadol are 
typically observed at around 1.25 hours after dosing. 
Dose-proportional increases in the Cmax and AUC values of tapentadol have been observed over 
the 50 to 150 mg dose range. 
A multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a 
mean accumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-
O-glucuronide, which are primarily determined by the dosing interval and apparent half-life of 
tapentadol and its metabolite. 
Food Effect 
The AUC and Cmax increased by 25% and 16%, respectively, when Nucynta® was administered 
after a high-fat, high-calorie breakfast. Nucynta® may be given with or without food. 
Distribution 
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Tapentadol is widely distributed throughout the body. Following intravenous administration, the 
volume of distribution (Vz) for tapentadol is 540 +/- 98 L. The plasma protein binding is low and 
amounts to approximately 20%. 
Metabolism and Elimination 
In humans, the metabolism of Tapentadol Hydrochloride is extensive. About 97% of the parent 
compound is metabolized. Tapentadol is mainly metabolized via Phase 2 pathways, and only a 
small amount is metabolized by Phase 1 oxidative pathways. The major pathway of tapentadol 
metabolism is conjugation with glucuronic acid to produce glucuronide. After oral administration 
approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) of the dose is excreted 
in urine in the conjugated form. A total of 3% of drug was excreted in urine as unchanged drug. 
Tapentadol is additionally metabolized to N-desmethyl tapentadol (13%) by CYP2C9 and 
CYP2C19 and to hydroxyl tapentadol (2%) by CYP2D6, which are further metabolized by 
conjugation. Therefore, drug metabolism mediated by cytochrome P450 system is of less 
importance than phase 2 conjugation. 
None of the metabolites contributes to the analgesic activity. 
Tapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys. The 
terminal half-life is on average 4 hours after oral administration. The total clearance is 1530 +/- 
177 ml/min. 
Special Populations 
Elderly 
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The mean exposure (AUC) to tapentadol was similar in elderly subjects compared to young 
adults, with a 16% lower mean Cmax observed in the elderly subject group compared to young 
adult subjects. 
Renal Impairment 
AUC and Cmax of tapentadol were comparable in subjects with varying degrees of renal 
function (from normal to severely impaired). In contrast, increasing exposure (AUC) to 
tapentadol-O-glucuronide was observed with increasing degree of renal impairment. In subjects 
with mild, moderate, and severe renal impairment, the AUC of tapentadol-O-glucuronide are 1.5-
, 2.5-, and 5.5-fold higher compared with normal renal function, respectively. 
Hepatic Impairment 
Administration of Nucynta® resulted in higher exposures and serum levels to tapentadol in 
subjects with impaired hepatic function compared to subjects with normal hepatic function. The 
ratio of tapentadol pharmacokinetic parameters for the mild and moderate hepatic impairment 
groups in comparison to the normal hepatic function group were 1.7 and 4.2, respectively, for 
AUC; 1.4 and 2.5, respectively, for Cmax; and 1.2 and 1.4, respectively, for t1/2. The rate of 
formation of tapentadol-O-glucuronide was lower in subjects with increased liver impairment. 
Pharmacokinetic Drug Interactions 
Tapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity 
system; therefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to 
occur. Naproxen and probenecid increased the AUC of tapentadol by 17% and 57%, 
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respectively. These changes are not considered clinically relevant and no change in dose is 
required. 
No changes in the pharmacokinetic parameters of tapentadol were observed when 
acetaminophen and acetylsalicylic acid were given concomitantly. 
In vitro studies did not reveal any potential of tapentadol to either inhibit or induce cytochrome 
P450 enzymes. Thus, clinically relevant interactions mediated by the cytochrome P450 system 
are unlikely to occur. 
The pharmacokinetics of tapentadol were not affected when gastric pH or gastrointestinal 
motility were increased by omeprazole and metoclopramide, respectively. 
Plasma protein binding of tapentadol is low (approximately 20%). Therefore, the likelihood of 
pharmacokinetic drug-drug interactions by displacement from the protein binding site is low. 
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AIM AND OBJECTIVE OF THE STUDY 
                 Analytical chemistry may be defined as the science and art of determining the 
composition of materials of the elements or compounds contained. 
 Importance of analytical chemistry is to gain information about the qualitative and 
quantitative composition of substance and chemical species, that is, to find out what a substance 
is composed of and exactly how much it is present. 
           Drug analysis plays an important role in the development of drugs, their 
manufacture and therapeutic use. Pharmaceutical industries rely up on quantitative chemical 
analysis to ensure that the raw material used and the final product obtained meets the required 
specification. For the estimation of drug present in dosage forms, HPLC, HPTLC, and UV-
Spectroscopic methods are considered to be the most suitable. These methods are powerful, 
extremely precise, accurate, sensitive, specific, linear and rapid in analyzing the sample.  The 
chromatographic methods was found to be most suitable than the UV-Spectroscopic due to its 
very high sensitivity. 
 These methods are powerful, extremely precise, accurate, sensitive, specific, 
linear and rapid in analyzing the sample.  
    Tapentadol Hydrochloride is a centrally acting analgesic, agonist at the mu-opioid receptor 
activity and the inhibition of nor-epinephrine reuptake. 
From the extensive literature review it was found that no method have been reported for 
estimation of Tapentadol Hydrochloride by using RP-HPLC method,  
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The present study is planned to develop an analytical method for the determination of 
Tapentadol Hydrochloride in tablet dosage form by RP-HPLC method under different 
chromatographic conditions. 
The reasons for developing RP-HPLC method for determination of this drug in tablet 
dosage form is as follows: 
1. To develop new RP-HPLC Method by Isocratic Mode. 
2. To develop a less run time Method. 
3.  To carry out estimation of Tapentadol Hydrochloride by using different 
chromatographic conditions. 
Advantages of less run time in HPLC: 
 It’s beneficial to the company economically. 
 To estimate the different compounds with less time in different formulations like tablets, 
capsules, syrups, expectorants and injections.  
 Utilisation of minimum solvent. 
 Reduce the cost. 
 Less utilisation of men, machine and materials. 
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PLAN OF WORK 
 The work plan was to develop Method for Tapentadol Hydrochloride and the plan 
of present work is as follows: 
HPLC: 
The work was plan to divide into three phases 
Phase I: 
Optimization of chromatographic conditions  
¾ Selection of wavelength  
¾ Selection of initial separation conditions   
¾ Selection of mobile phase (pH, peak modifier, solvent strength, ratio and 
flow rate) 
¾ Nature of the stationary phase 
¾ Selection of internal standard 
¾ Selection of separation method and agent 
Phase II: 
Validation of the method 
The developed method were proposed to be validated using the various validation 
parameters such as,  
¾ Accuracy 
¾ Precision 
¾ Linearity and of detection (LOD) / Limit of quantitation (LOQ) 
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¾ Selectivity / Specify 
¾ System suitability. 
Phase III: 
Estimation of Tapentadol Hydrochloride in a branded tablet dosage form “NIAP”.  
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METHODOLOGY 
RP-HPLC Method Development and Validation for the Estimation of Tapentadol 
Hydrochloride in Marketed Tablet dosage form  
MATERIALS AND ISTRUMENTS USED 
a) Drug sample & Study products 
Tapentadol Hydrochloride was obtained from MSN Laboratories Ltd, Hyderabad, India. 
Test product:  
Tapentadol Hydrochloride (niap) (Reddy’s Laboratories Ltd) Tablets were purchased from the 
local market. 
b) Chemicals and solvents used for estimation: 
• HPLC Water    – Qualigens, Mumbai, India. 
• Acetonitrile    – Rankem, Mumbai, India. 
• Distilled water    – Double Distilled water.  
• Potassium dihydrogen phosphate  – M.R.Fine chem, Banglore. 
• NaOH Base   – Manas chemicals, Mumbai. 
c) Instruments used: 
• Elico pH meter LI 127. 
• Water 2695 AT HPLC. 
• Photo diode array detector (waters 2996) 
• Shimadzu 1700 UV Spectrophotometer. 
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• Sonica Ultrasonic cleaner.  
• Solvent filtration unit – Millipore. 
• Shimadzu electronic balance AX 200. 
• Ultra Cooling centrifuge – Remi, India. 
OPTIMIZATION OF CHROMATOGRAPHIC CONDITION FOR THE ESTIMATION 
OF TAPETADOL HYDROCHLORIDE 
Selection of wavelength 
An UV spectrum of 10 µg/ml Tapentadol Hydrochloride in water was recorded by 
scanning in the range of 200 nm to 400 nm. From the UV spectrum wavelength of 215 nm was 
selected. At this wavelength Tapentadol Hydrochloride showed good absorbance.  
Selection of chromatographic method 
Proper selection of the method depends upon the nature of the sample 
(ionic/ionisable/neutral molecule), its molecular weight and solubility. The drug selected in the 
present study is polar in nature and hence the reverse phase HPLC was selected for the initial 
separations because of its simplicity and suitability. 
Initial separation conditions 
 Standard solution:  10 μg/ml of Tapentadol Hydrochloride in HPLC grade water. 
 Equipment 
  System      : Water 2695 AT HPLC. 
Pump         : waters 2695 prominence solvent delivery system 
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  Detector    :  Photo diode array detector (waters 2998) 
Injector     : Auto-sampler  
Chromatographic conditions  
     Stationary phase  :  Phenomenex C18 Column 
                        Mobile phase   : Solvent A: 0.5% glacial acetic acid                                                
                                                        Solvent B: Acetonitrile  
     Solvent ratio   : 50:50 
      Detection   : 215 nm 
  Flow rate   : 1.0 ml/min 
      Sample size   : 20 μl 
       Needle wash   : water HPLC grade  
            Column temperature             : room temperature (20ºC) 
Chromatographic condition 1 
 Stationary phase  : Phenomenex C18 Column 
 Mobile phase    : Solvent A: 0.5% Glacial acetic acid   (pH- 3.5) 
                                                Solvent B: Acetonitrile + Methanol (50+50) 
 Solvent ratio   : 60:40(A: B) 
 Detection   : 215 nm 
 Flow rate   : 1.0 ml/min 
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Chromatographic condition 2 
 Stationary phase  :  Phenomenex C18 Column 
 Mobile phase    : Solvent A: ortho phosphoric acid (pH- 3.5) 
                                           Solvent B: Acetonitrile + Methanol (50+50) 
 Solvent ratio   : 70:30(A: B) 
 Detection   : 215 nm 
 Flow rate   : 0.9 ml/min 
Chromatographic condition 3 
 Stationary phase  :  Phenomenex C18 Column 
 Mobile phase    : Solvent A: Water 
                                             Solvent B: Acetonitrile + Methanol (50+50) 
 Solvent ratio   : 70:30(A: B) 
 Detection   : 215nm 
 Flow rate   : 1.0 ml/min 
Chromatographic condition 4 
 Stationary phase  :  Phenomenex C18 Column 
 Mobile phase    : Solvent A: Water 
                                            Solvent B: Acetonitrile  
 Solvent ratio   : 75:25(A: B) 
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 Detection   : 215 nm 
 Flow rate   : 1.3 ml/min 
Chromatographic condition 5 
 Stationary phase  :  Phenomenex C18 Column 
 Mobile phase    : Solvent A: Water 
                                           Solvent B: Methanol  
 Solvent ratio   : 75:25(A: B) 
 Detection   : 215nm 
 Flow rate   : 1.0 ml/min 
 
Effect of ratio of mobile phase 
 Phosphate Buffer and Methanol with 50:50, 70:30, 40:60 and 85:15 ratios were used as 
the mobile phase. At 50:50 ratio, the symmetric peak was eluted at 4.26 for Tapentadol 
Hydrochloride. At 70:30 and 75:25 ratios the peaks were asymmetric. Thus for the present study 
50:50 ratio mobile phase system was selected. 
Effect of flow rate 
 Flow rate of 1.0 to 1.5 ml/min were used and chromatograms were recorded. When 1.23 
ml/min was used, elution time of peak was 4.26. This flow rate gave symmetric and well retained 
peak. So for the present study, 1.23 ml/min was selected. 
Dept. of Pharmaceutical Analysis                                                                                                      Methodology                            
 
KMCH college of pharmacy  Page 54   
Finally, the following Fixed Chromatographic Conditions were selected for the estimation of 
Tapentadol Hydrochloride.  
 Stationary phase  : Phenomenex C18 Column 
 Mobile phase    : Solvent A: Phosphate Buffer adjusted to Ph 7  
                                                              With NaOH, Solvent B: Acetonitrile  
 Solvent ratio   : 50:50(A: B) 
 Detection   : 215 nm 
 Flow rate   : 1.23 ml/min 
 Sample size   : 20 µl 
 Needle wash   : Water HPLC grade  
 Column temperature   : Room temperature of above 200C 
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QUANTIFICATION AND VALIDATION 
Preparation of Standard Stock Solution 
Standard stock solution of 1000 µg/ml of Tapentadol Hydrochloride was prepared using HPLC 
grade water. Further, 50µg/ml solution was prepared from the stock solution by appropriate 
dilution with mobile phase. Working standard solution was prepared by diluting the 0.5, 0.75, 
1.0, 1.25, and 1.50ml of standard solution with 10 ml of mobile phase to give the concentration 
of 50-150 µg/ml. All the solutions are filtered through 0.45µ GHP filter. 
Preparation of Sample Solution 
Weigh accurately 6 tablets of Tapentadol Hydrochloride. Take powder equivalent to 
50mg in a 50 ml volumetric flask. Dissolve it with water, sonicate for 10min and make up the 
volume with the same solvent. From this above stock solution pipette out 1ml to10ml 
volumetric flask and make up the volume with mobile phase containing 50:50 ratio and filter 
through 0.45µ GHP filter. 
Recording of chromatogram  
After optimization of chromatographic conditions mentioned above, a steady baseline for about 
8min was recorded. After the stabilization of the baseline, 100 μg/ml of the standard solution 
was injected and chromatogram was recorded until the reproducibility of the peak areas was 
found satisfactory. The standard solutions containing 50-150 µg/ml of Tapentadol Hydrochloride 
was injected and chromatograms were recorded. 
Retention time of Tapentadol Hydrochloride was found to be 4.23 and shown in Fig: 8, 9, 
10, 11 and 12 respectively. 
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The procedure was repeated using for the both sample and standard solutions and the 
chromatogram was shown in Fig: 7, 13.  
Calibration curves were plotted using peak area against concentration of corresponding 
standard solutions. Peak areas of the sample chromatograms were reordered and the amount of 
Tapentadol Hydrochloride was calculated from the regression equation. 
VALIDATION OF THE HPLC METHOD  
Validation is a process of establishing documented evidence, which provides a high 
degree of assurance that a specific activity will consistently produce a desired result or product 
meeting its predetermined specifications and quality characteristics. 
Method validation is the process of demonstrating that analytical procedures are suitable 
for their intended use and that they support the identity, quality, purity, and potency of the drug 
substances and drug products. Simply, method validation is the process of proving that an 
analytical method is acceptable for its intended purpose. A successful validation guarantees that 
both the technical and regulatory objectives of the analytical methods have been fulfilled. The 
transfer of a method is best accomplished by a systematic method validation process. The real 
goal of validation process is to challenge the method and determine limits of allowed variability 
for the conditions needed to run the method. 
Significance of Method Validation: 
The quality of analytical data is a key factor in the success of a drug development program. The 
process of method development and validation has a direct impact on the quality of these data. 
• To trust the method. 
• Regulatory requirement. 
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Analytical validation is a very important feature of any package of information submitted 
to international regulatory agencies in support of new product marketing or clinical trials 
applications. A thorough method development can almost rule out all potential problems, at the 
same time, a thorough validation programmed can address the most common ones and provide 
assurance to the intended purpose (can be used with 100% confidence). In other words, a 
thorough validation can fulfill all the technical and regulatory objectives. A direct consequence 
and most significant out come from any method validation exercise is ‘the development of 
meaningful specifications can be predicted upon the use of validated analytical procedures that 
can assess changes in a drug substance or drug product during its life time. 
Analytical characteristics listed below may not be applicable to every test procedure or 
every particular material. It will mostly depend on the purpose for which the procedure is 
required, however, these following aspects of validation should be given due importance. 
VALIDATION OF THE METHOD  
The development of HPLC method for the estimation of Tapentadol Hydrochloride in a 
dosage form, validation of the method was performed. The validation procedure for the 
developed method is as follows. 
a) Accuracy: 
Accuracy of the method was determined by recovery experiments. The reference 
standards of the respective drug were added to the sample solution at the level of 50% (6), 100% 
(3) and 150% (6). These were further diluted by procedure as followed in the estimation of 
formulation. The concentrations of the drugs present in the resulting sample solution were 
determined by using assay method. 
Dept. of Pharmaceutical Analysis                                                                                                   Quantification                            
 
KMCH college of pharmacy  Page 58 
b) Precision: 
Repeatability and reproducibility studies were carried out for the precision of the method. 
Repeatability studies were done by consequently injecting the standard solution of same 
concentration i.e., 100 µg/ml of Tapentadol Hydrochloride (n=6). These solutions were prepared 
in duplicate and injected as per assay procedure. 
c) Linearity and range: 
From the standard stock solutions, a series of standard solution was prepared to contain 
50µg/ml to 150µg/ml. The solutions were examined by the assay procedure. The calibration 
curve was plotted using peak area Vs concentration of the standard solution. From the calibration 
curve, the slope and intercept were calculated. 
d) Limit of detection (LOD) and Limit of quantification (LOQ): 
The LOD and LOQ were separately determined and reported in table no: 9, based on the 
calibration curve of standard solution. The residual standard deviation of the regression line or 
the standard deviation of y – intercepts of regression lines may be used to calculate LOD and 
LOQ. LOD = 3.3 × D/S and LOQ = 10 × D/S, where, D is the Standard deviation of y – 
intercepts of regression line and S is the slope of the calibration curve. 
e) System Suitability Studies: 
The system suitability studies were carried out as specified in USP. These parameters 
include column efficiency, resolution and capacity factor. 
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g) Ruggedness: 
The sample was analyzed by a different chemist in the same instruments on a different day and 
the results are as follows: 
1) First Chemist: 
For tablet: 
Tapentadol Hydrochloride:   50 mg / average weight of the tablet 
2) Second chemist: 
For tablet: 
Tapentadol Hydrochloride:   50 mg / average weight of the tablet 
The deviation between the results of the two chemists is 0.47% for Tapentadol 
Hydrochloride. Limit was not more than 2.0%. 
The system suitability was also found to be within the limits. 
The deviation among the results obtained by two chemists on a different day is well within the 
limits. Hence the method is rugged. 
Capacity factor (k') is a measured of how well the sample molecule is retained by a 
column during an isocratic separation .The ideal value of (k') ranges from 2-10. 
Capacity Factor (k') = V1 – V0 / V0 
Where, V1 is the retention volume at the apex of the peak (solute)   and V0 is the void 
volume of the system. 
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Resolution (Rs) is the difference between the retention times of two solutes divided by 
their average peak width. The ideal value of (Rs) is 1.5 
Resolution (Rs) = Rt1 –Rt2 /0.5(W1-W2) 
Where, Rt1 and Rt2 are the retention times of component 1 and 2, respectively. 
Selectivity (α) is a measured of relative retention of two components in a mixture. The 
ideal value of α is 2 
Selectivity (α) = V2 –V0 / V1 –V0 
Where, V0 is the void volume of column and V2 and V1 are the retention volume of the 
second and first peaks, respectively. 
Efficiency (N) of a column is measured by the number of theoretical plates per meter 
.Column with N ranging from 5,000 to 100,000 plates/meters are ideal for good separation. 
Column efficiency (N) = Rt2 / W2 
Where Rt is the retention time and W is the peak width. 
Peak asymmetry factor can be used as a criterion of column performance. For a well 
packed column, an asymmetry factor of 0.9 to 1.1 should be achievable. 
Peak asymmetry factor (As) = b / a 
Where a and b are the distances on either side of the peak midpoint. 
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RESULTS AND DISCUSSION 
HPLC METHOD             
 A RP-HPLC method was developed for the estimation of Tapentadol Hydrochloride in 
tablet dosage form, which can be conveniently employed for routine quality control in 
pharmaceutical dosage forms. The peak area of standard and sample solutions was calculated. 
The assay procedures were repeated for 6 times and mean peak area, mean weight of standard 
drugs, mean weights of sample taken for assay were calculated.  
The percentage of drug found in formulation, mean and relative standard deviation were 
calculated and presented in   Table 4. The result of analysis shows that the amount of drug 
present in the formulation has a very good correlation with the label claim of the formulation.  
Validation of the method 
The accuracy of the method was determined by recovery experiments. A known quantity 
of the pure drug was added to the pre-analyzed sample formulations at 50%, 100% and 150% 
levels.  The recovery studies were carried out 6 times of each level and the percentage recovery 
and percentage relative standard deviation were calculated and given in Table 5.  
The percentage recovery of Tapentadol Hydrochloride was found to be in the range of 
99.6% and 100.26% respectively from the data obtained, it was observed that the recoveries of 
standard drugs were found to be accurate and within the specified limits.  
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Table no: 4 Analysis of Formulations 
 
 
*each value is a mean of six observations 
The precision of the method was determined by inter day and intraday studies. The area 
of drug peak and percentage relative standard deviation of intraday and inter day were calculated 
and presented in Table 6(a) and 6(b) respectively. The results revealed that the developed 
method was found to be reproducible in nature. 
1. Accuracy, precision and recovery: 
Table no 5: Accuracy (Recovery studies) 
 
Drug 
Label 
Claim   
mg/tab 
 
Spike 
Level 
(%) 
Amount    
of drug 
added 
(mg) 
Amount 
of drug 
recovered 
(mg) 
Mean 
Peak area
 
Percentage 
Recovery 
 
%RSD* 
 
 
Tapentadol 
Hydrochlorid
e  
 
 
 
50 
50 
 
50 49.56  
80253.6 
 
100.26 
 
0.57 
100 
 
100 99.43  
159405.5 
 
101.4 
 
0.56 
150 
 
150 150.24  
236914 
 
99.6 
 
0.63 
*-Each value is a mean of six observations.  
 
 
Drug 
Label 
Claim 
(mg/tablet) 
 
Estimated 
Amount 
(mg/tablet) 
 
 
% Label 
Claim 
 
 
%RSD* 
 
 Tablet 
 
 50.0    
 
       49.93 
 
99.88 
 
     0.3944 
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Acceptance Criteria: 
                   For an assay method, mean recovery will be 100% ± 2% at each concentration over 
the range of 50-150% of the target concentration. From the data obtained, it was observed that 
the recoveries of standard drugs were found to be accurate and within the specified limits. 
2. Precision 
Table 6(a): Intraday Studies 
No of 
Injection 
Conc.   of Tapentadol 
Hydrochloride 
(µg/ml) 
 
Peak Area 
 
% RSD 
 
 
 
6 
 
 
 
 
100 
 
 
 
 
159490 
158750 
159324 
159545 
158905 
159410 
 
 
 
0.9 
*-Each value is a mean of six observations.  
Acceptance criteria 
              The % relative standard deviation of peak areas of Tapentadol Hydrochloride should not 
be more than 2.0 
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Table no 6b: Inter day studies 
Day 
Conc. of  Tapentadol 
Hydrochloride 
(µg/ml) 
 
Peak Area % RSD 
0Day 1 
 
50 
 
80270 
80256 
80235 
80545 
80385 
81395 
 
0.83 
Day 2 100 
 
159540 
159425 
159485 
159360 
159365 
159580 
0.65 
 
Day 3 150 
 
237982 
240195 
233165 
239423 
236540 
240882 
 
 
0.71 
 
Acceptance criteria 
              The % relative standard deviation of peak areas of   Tapentadol Hydrochloride should 
not be more than 2.0 
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3. Linearity: 
   Tapentadol Hydrochloride was found to be linear in the range of 50 to 150µg/ml and 
shown in the table no: 7. The correlation coefficient of Tapentadol Hydrochloride was found to 
be 0.999.The calibration curves were plotted as peak area Vs concentration of the standard 
solutions (Fig: 4).  
The calibration graph shows that linear response was obtained over the range of 
concentrations used in the assay procedure. The range demonstrates that the method is linear 
outside the limits of expected use. 
Table no: 7 Linearity range of Tapentadol Hydrochloride 
 
S.NO. 
Conc. of Tapentadol 
Hydrochloride (μg/ml) 
Peak area of 
Tapentadol Hydrochloride 
1 50 80252 
2 75 121487 
3 100 159408 
4 125 197643 
5 150 236917 
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Fig 17: Calibration curve of Tapentadol Hydrochloride 
 
Fig: 4 Linearity curve of Tapentadol Hydrochloride 
Acceptance Criteria 
Coefficient of correlation should be not less than 0.999 
4. Ruggedness:                                     
Table no 8: Ruggedness studies correction 
 
Drug name 
Concentration 
(µg/ml) 
 
Mean peak area 
 
%RSD 
Day-1 analyst-1 
Tapentadol 
Hydrochloride  
 
50 
 
80252 
 
0.615 
Day-2 analyst-2 
Tapentadol 
Hydrochloride  
 
50 
 
83048 
 
0.613 
 
y = 1577.x + 1195.
R² = 0.999
0
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The sample was analyzed by a different chemist and same instruments on a different day 
have been performed. 
          The deviation among the results obtained by two chemists on a different day is well within 
the limits. Hence the method is rugged. 
5. Limit of Detection and Limit of Quantification: 
The LOD is the smallest concentration of the analyte that gives a measurable response 
(signal to noise ratio of 3.3). LOD of Tapentadol Hydrochloride was found to be128.88. The 
LOQ is the smallest concentration of the analyte, which gives response that can be accurately 
quantified (signal to noise ratio of 10). The LOQ of Tapentadol Hydrochloride was found to be 
390.54. 
6. System Suitability: correction 
The system suitability studies were performed for the standard solution and were 
presented in Table no: 9. the values obtained demonstrated the suitability of the system for the 
analysis of the above drug combination.  
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Table no: 9 System suitability studies 
 
Validation Parameters 
 
Tapentadol 
Hydrochloride  
 
         
 
 
 
Linearity range (µg/ml) 
 
Correlation co-efficient (r2) 
 
LOD (µg/ml) 
 
LOQ (µg/ml) 
 
Intraday (%RSD)* 
 
Interday (%RSD)* 
 
Accuracy (%) 
 
Resolution factor (Rs) 
 
No. of theoretical plates (N) 
 
Capacity factor (K’) 
 
High equivalent to theoretical 
plates (HETP) 
 
Tailing factor 
 
 
 
50-150 
 
0.999 
 
128.88 
 
390.54 
 
0.9 
 
0.73 
 
99.6-100.26 
 
1.38 
 
2032.49 
 
0.36 
 
32.69 
 
 
0.68 
                  *-Each value is a mean of six observations. 
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Fig: 5 Chromatogram of Blank without Standard/drug 
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Fig: 6 Chromatogram of Placebo 
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Fig: 7 Standard chromatogram of Tapentadol Hydrochloride (100ug/ml) 
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  Fig: 8 Chromatogram of Linearity Standard solution of Tapentadol Hydrochloride 
(50ug/ml) 
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Fig: 9 Chromatogram of Linearity Standard solution of Tapentadol Hydrochloride 
(75ug/ml) 
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Fig: 10 Chromatogram of Linearity Standard solution of Tapentadol Hydrochloride 
(100ug/ml) 
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Fig: 11 Chromatogram of Linearity Standard solution of Tapentadol Hydrochloride 
(125ug/ml) 
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Fig: 12 Chromatogram of Linearity Standard solution of Tapentadol Hydrochloride 
(150ug/ml) 
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Fig: 13 chromatogram of sample solution 
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SUMMARY AND CONCLUSION 
The working condition for the HPLC method was established for Tapentadol Hydrochloride and 
then was applied on pharmaceutical dosage forms. A simple Reverse Phase High Performance 
Liquid Chromatographic method has been developed and subsequently validated.  
        The separation method was carried out by using a mobile phase consisting of Acetonitrile 
and potassium dihydrogen phosphate pH 7±0.05 in the ratio 50:50. The detection was carried out 
by using PDA detector at 215nm. The column was Phenomenex C18 (250 X 4.6mm 5 µ). The 
flow rate was selected as 1.23ml/min.  
        The retention time of Tapentadol Hydrochloride was found to be 4.2. The asymmetry factor 
or tailing factor of Tapentadol Hydrochloride was found to be -1.38, which indicates 
symmetrical nature of the peak. The number of theoretical plates of Tapentadol Hydrochloride 
was found to be 2032.49, which indicates the efficient performance of the column. These 
parameters represent the specificity of the method. 
       From the linearity studies, specified concentration levels were determined. It was observed 
that Tapentadol Hydrochloride was linear in the range of 50% to 150% for the target 
concentration by RP-HPLC. The linearity range of Tapentadol Hydrochloride 50-150µg/ml was 
found to obey linearity with a correlation coefficient of 0.999.  
              The validation of the proposed method was verified by system precision and method 
precision by RP-HPLC. The %RSD of system suitability for Tapentadol Hydrochloride was 
found to be 0.81.  
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The validation of the proposed method was verified by recovery studies. The percentage 
recovery range was found to be satisfied which represent in results. The ruggedness study was 
also performed.  
CONCLUSION: 
A HPLC method for Tapentadol Hydrochloride was developed and validated in tablet 
dosage form as per ICH Guidelines. 
Waters 2996 series with PDA Detector and Phenomenex C18 (250x4.6mm, 5µ) column, 
injection of 20 µl is injected and eluted with the mobile phase of potassium dihydrogen 
phosphate buffer with  pH 7 and Acetonitrile in the ratio 50:50, which was pumped at a flow rate 
of 1.23 ml at 215nm. The peak of Tapentadol Hydrochloride was found well separated at 4.2 
min. The developed method was validated for various parameters as per ICH guidelines like 
system suitability, accuracy, precision, linearity, specificity, ruggedness, robustness and solution 
stability. 
The analytical method validation of Tapentadol Hydrochloride by RP HPLC was found to be 
satisfactory and could be used for the routine pharmaceutical analysis of Tapentadol 
Hydrochloride. 
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GLOSSARY 
1. Degassing: The process of removing dissolved gas from the liquid mobile phase before or 
during use. Degassing is done by heating, by vacuum, or by helium purging. 
2. Drift: The change in the baseline value over time, expressed mathematically as the slope 
of the least line squares line fitted to the base line in a specified region chromatogram. 
3. Eluent: Mobile phase used to perform a chromatographic separation .The liquid that exits 
through a chromatographic column during a separation. 
4. Equilibration: The process of bringing a chromatographic solvent (solvent, column, and 
interactive surfaces) to a thermally and chemically stable state, usually indicated by a drift 
–free base line. 
5. External Standard: A separate sample that contains known quantities of the same 
compounds that are in unknown samples. External standards are used for quantitation by 
matching the detector response of a component peak to a point on a calibration curve for 
that component. The calibration curve is generated from a separately processed standard 
(or set of standards). 
6. Fronting peak: An asymmetrically shaped chromatographic peak in which the front part 
of the peak (before the apex) contains more area than the rear of the peak. The asymmetry 
factor for fronting peak has value less than one. The opposite of fronting peak is a tailing 
peak  
7. Fused peak: Two or more no baseline-resolved peaks in a chromatogram that share the 
same base line, the same base line start and end points, and the same slope and offset. 
8. Gradient Elution: Also called as solvent programming, a technique for decreasing the 
separation time by increasing the mobile phase strength over time during a 
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chromatographic separation. Gradients can be continuous or stepwise. Binary (2-solvent), 
ternary (3-solvent0 and quaternary (4-solvent) gradients are used routinely in HPLC. 
9. Integration: The mathematical process of calculating an area such as a chromatographic 
peak that is bounded in a part or in a whole by a curved line. 
10. Isocratic: The condition in which the solvent composition, flow rate, and the temperature 
are constant during a chromatographic run, the condition in which the solvent composition 
is constant during a chromatographic run. 
11. Linearity: The condition in which detector response is directly proportional to the 
concentration or amount of a component over a specified range of component 
concentrations or amounts .A calibration curve is a straight line when the standard 
concentrations are within the linear response range of the detector. In chromatography, 
accurate quantitation requires linearity of the detector response over the range of actual 
sample concentrations or amounts. 
12. Mobile Phase: The fluid (gas or liquid) that carries solutes through a chromatographic 
column. In LC, the liquid that is pumped through the fluid path of the chromatographic 
system and into which the samples are injected.  
13. Plate count: A measure of the observed chromatographic resolution based on its 
equivalency to the number of theoretical plates that would provide the same resolution. 
14. Resolution: The extent to which a chromatographic column separates components from 
each other.  Mathematically defined, resolution is the difference between the peak retention 
time of a selected peak and the peak preceding its multiplied by a constant of 1.18,then 
dived by the sum of the peak widths at 50%of peak height. It is used to monitor the 
separation of eluting components and to establish system efficiency. 
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15. Retention Time: The time that elapses between the injection of a sample and the 
appearance of the peak maximum of a component in a sample. 
16. RT ratio: The Retention Time of a component divided by the retention time of its 
reference peak. 
17. System suitability: An application that applies a set of standard criteria to test if an entire 
chromatographic system and the methodology are working within acceptable limits. 
Empower software bases the system suitability tests on standard laboratory calculations, 
including United States Pharmacopoeia (USP) guidelines and calculations. Empower 
software produces reports showing statistical accuracy and reproducibility of the 
chromatographic system data.  
18. Tailing Factor: A measure of peak symmetry, where a Symmetrical peak has a tailing 
factor of 1.As Tailing increases, peak symmetry increases for System suitability, the tailing 
factor is the width of the peak at 5% height, divided by two times the distance from the 
peak maximum to the leading edge of the peak (where the distance is measured at point 5 
% of the peak height from the base line). 
19. Capacity factor: A chromatographic parameter that measures retention time of a sample 
molecule relative to the column dead volume.  
20. Acceptance Criteria: Numerical Limits, ranges, or other suitable for acceptance of the 
results of analytical procedures. 
21. Detection Limit: The detection limit of an individual analytical procedure is the lowest 
amount of analyte in a sample that can be detected, but not necessarily quantitated as an 
exact value. 
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22. Drug Product: A finished dosage form, for example, a capsule, tablet, or solution that 
contains a drug substance, but not necessarily, in association with one or more other 
ingredients. 
23. Drug Substance/Active Ingredient: An active ingredient that is intended to furnish 
pharmacological activity or other direct effect the structure or any function of the human 
body. The active ingredient does not include intermediates used in the synthesis of such 
ingredient. The term includes those components that may undergo chemical change in the 
manufacture of the drug product and be present in the drug product in a modified form 
intended to furnish the specified activity or effect. 
24. Reagent: For analytical procedures, any substance used in a reaction for the purpose of 
detecting, measuring, examining, or analyzing other substances. 
25. Specification: The quality standards (i.e., tests, analytical procedures, and acceptance 
criteria) provided in an approved application to confirm the quality of the drug substances, 
drug products, intermediates, raw materials, reagents, and other components including 
container closure systems, and in-process materials. 
26. Spiking: The addition of a small known amount of a known compound to a standard, 
sample, or placebo, typically for the purpose of confirming the performance of an 
analytical procedure or the calibration of an instrument. 
27. Working Standard: A standard that is qualified against and used instead of the reference 
standard (also known as in-house or secondary standard). 
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